Drugs / LLP2A-ALENDRONATE
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT03197623 | Oct 2016 → Mar 2021 | osteonecrosis, osteoporosis | Nancy E. Lane, MD | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | LLP2A-ALENDRONATE | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03197623 ↗ |
| Modality | Small molecule | “A small molecule, LLP2A-Ale” NCT03197623 ↗ |
| Route | Intravenous | “Single administration of LLP2A-Ale given intravenously over 120 minutes.” NCT03197623 ↗ |